Document:

Exhibit 4.1

Exhibit 4.1

AMENDMENT AGREEMENT

AMENDMENT AGREEMENT (this “Agreement”), dated as of October 28, 2009, by and among Image
Entertainment, Inc., a Delaware corporation, with headquarters located at 20525 Nordhoff Street,
Suite 200, Chatsworth, California 91311 (the “Company”), and Portside Growth and Opportunity Fund
(the “Investor”).

WHEREAS:

A. The Company executed that certain Amended and Restated Senior Secured Convertible Note in
favor of the Investor, originally issued as of August 30, 2006 and as amended as of July 30, 2009
pursuant to the terms of the Second Amendment and Exchange Agreement dated as of July 30, 2009 by
and among the Company and the Investor (the “Amendment and Exchange Agreement”), in the principal
amount of $15,700,972.60 (the “Amended and Restated Note”).

B. The Company and the Investor desire to enter into an amendment to the Amended and Restated
Note as set forth herein. Capitalized terms used herein and not otherwise defined herein shall
have the respective meanings ascribed to them in the Amended and Restated Note, as amended hereby
or in the Amendment and Exchange Agreement, as appropriate.

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises hereinafter
set forth, the Company and the Investor hereby agree as follows:

1. AMENDMENT TO AMENDED AND RESTATED NOTE.

(a) Effective as of the execution of this Agreement by the Company and the Investor and the
payment of the Legal Fees, the defined term “Contingent Installment Date,” as defined in Section
(28)(j) of the Amended and Restated Note, is hereby amended in its entirety to read as follows:

(j) “Contingent Installment Date” means (x) if the Company has entered into
a written agreement with a bona fide purchaser prior to November 15, 2009
that, upon consummation of the transaction contemplated thereby, would
result in a Change of Control of the Company and its Subsidiaries, November
30, 2009 (or such earlier date such agreement has been terminated or
otherwise ceases to be in full force and effect, solely to the extent such
date is after November 15, 2009) or (y) otherwise, November 15, 2009.

(b) Effective as of the execution of this Agreement by the Company and the Investor and the
payment of the Legal Fees, Section 8(a) of the Amended and Restated Note is hereby amended such
that the words “five (5) Trading Days prior to such Installment Date” in the first sentence of
Section 8(a) of the Amended and Restated Note are hereby replaced by the words “two (2) Trading
Days prior to such Installment Date”.

(c) Ratification. Except as otherwise expressly provided herein, the Securities
Purchase Agreement, the Amendment and Exchange Agreement and each other Transaction Document and the Security Documents, is, and shall continue to be, in full force
and effect and is hereby ratified and confirmed in all respects.

 

 

 

2. REPRESENTATIONS AND WARRANTIES.

(a) Each of the Investor and the Company hereby represents and warrants to the other party, as
of the date hereof:

(i) Each of the Investor and the Company has the requisite corporate power and
authority to execute and deliver this Amendment, and to perform its obligations hereunder
and under the Amended and Restated Note (as amended or modified hereby). The execution,
delivery and performance by each of the Company and the Investor of this Amendment have been
duly approved by all necessary corporate action and no other corporate proceedings are
necessary to consummate such transactions.

(ii) This Amendment has been duly executed and delivered by each of the Company and the
Investor. This Amendment is the legal, valid and binding obligation of each of the Company
and the Investor, enforceable against each of them in accordance with its terms, except as
such enforceability may be limited by general principles of equity or to applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws
relating to, or affecting generally, the enforcement of applicable creditors’ rights and
remedies, and is in full force and effect.

(b) The Company hereby represents and warrants to the Investor as of the date hereof:

(i) No Conflicts. The execution, delivery and performance of this Agreement by
the Company and the consummation by the Company of the transactions contemplated hereby and
thereby will not (i) result in a violation of any certificate of incorporation, certificate
of formation, any certificate of designations or other constituent documents of the Company
or any of its Subsidiaries, any capital stock of the Company or any of its Subsidiaries or
bylaws of the Company or any of its Subsidiaries or (ii) conflict with, or constitute a
default (or an event which with notice or lapse of time or both would become a default) in
any respect under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which the Company or any of its
Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including foreign, federal and state securities laws and regulations and
the rules and regulations of the Principal Market applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is
bound or affected.

(ii) Consents. Neither the Company nor any of its Subsidiaries is required to
obtain any consent, authorization or order of, or make any filing or registration with, any
court, governmental agency or any regulatory or self-regulatory agency or any other Person
in order for it to execute, deliver or perform any of its obligations under or contemplated by this Agreement, in each case in accordance with
the terms hereof or thereof.

 

2

 

3. FEES AND EXPENSES.

The Company agrees to reimburse the Investor for the actual legal fees and expenses of Schulte
Roth & Zabel LLP in connection with the review and negotiation of this Agreement (the “Legal
Fees”).

4. INSTALLMENT NOTICE.

Effective as of the execution of this Agreement by the Company and the Investor and the
payment of the Legal Fees, the Investor shall be deemed to have rescinded its Installment Notice
dated October 23, 2009.

5. MISCELLANEOUS.

(a) Counterparts. This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party;
provided that a facsimile signature shall be considered due execution and shall be binding upon the
signatory thereto with the same force and effect as if the signature were an original, not a
facsimile signature.

(b) Headings. The headings of this Agreement are for convenience of reference and
shall not form part of, or affect the interpretation of, this Agreement.

(c) Severability. If any provision of this Agreement is prohibited by law or
otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the
provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to
apply to the broadest extent that it would be valid and enforceable, and the invalidity or
unenforceability of such provision shall not affect the validity of the remaining provisions of
this Agreement so long as this Agreement as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially
impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable
provision(s) with a valid provision(s), the effect of which comes as close as possible to that of
the prohibited, invalid or unenforceable provision(s).

(d) Governing Law; Jurisdiction; Jury Trial. All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by the
internal laws of the State of New York, without giving effect to any choice of law or conflict of
law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts

 

3

 

sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof
to such party at the address for such notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO
REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR
ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

(e) No Third Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective permitted successors and assigns, and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

(f) Further Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other party may reasonably request in
order to carry out the intent and accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby.

(g) No Strict Construction. The language used in this Agreement will be deemed to be
the language chosen by the parties to express their mutual intent, and no rules of strict
construction will be applied against any party.

(h) Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective successors and assigns in accordance with the terms of
the Securities Purchase Agreement.

[Signature Page Follows]

 

4

 

IN WITNESS WHEREOF, the Investor and the Company have caused their respective signature page
to this Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	 	COMPANY:

IMAGE ENTERTAINMENT, INC.

 	 
	 	By:  	/s/ JEFF M. FRAMER
 	 
	 	 	Name:  	Jeff M. Framer 	 
	 	 	Title:  	President and CFO 	 

 

[Signature Page to Amendment Agreement]

 

	 	 	 	 	 

IN WITNESS WHEREOF, the Investor and the Company have caused their respective signature page
to this Agreement to be duly executed as of the date first written above.

	 	 	 	 	 
	 	INVESTOR:

PORTSIDE GROWTH AND OPPORTUNITY FUND

 	 
	 	By:  	/s/JEFFREY C. SMITH
 	 
	 	 	Name:  	Jeffrey C. Smith 	 
	 	 	Title:  	Authorized Signatory 	 
	 

 

[Signature Page to Amendment Agreement]exv4w11

Exhibit 4.11

OMEROS MEDICAL SYSTEMS, INC.

NOTICE OF STOCK OPTION GRANT

Pamela Pierce-Palmer, M.D., Ph.D.

140 Vasquez Avenue

San Francisco, California 94127

     You have been granted an option to purchase Common Stock of Omeros Medical Systems, Inc. (the
“Company”) as follows:

	 	 	 
	Board Approval Date:

	 	December 11, 2001
	 
	 	 
	Date of Grant (Later of Board
	 	 
	Approval Date or Commencement
	 	 
	of Employment/Consulting):

	 	December 11, 2001
	 
	 	 
	Exercise Price per Share:

	 	$0.265 
	 
	 	 
	Total Number of Shares Granted:

	 	55,781 
	 
	 	 
	Total Exercise Price:

	 	$14,781.97 
	 
	 	 
	Type of Option:

	 	Nonstatutory Stock Option
	 
	 	 
	Expiration Date:

	 	December 11, 2011
	 
	 	 
	Vesting Commencement Date:

	 	December 11, 2001
	 
	 	 
	Vesting/Exercise Schedule:

	 	This Option may be exercised, in whole or in part, at any time
after the Date of Grant. The Shares underlying this Option shall be fully vested on
the Vesting Commencement Date.
	 
	 	 
	Termination Period:

	 	This Option may be exercised for 90 days after termination of employment
or consulting relationship except as set out in Section 5 of the Stock Option Agreement
(but in no event later than the Expiration Date). Optionee is responsible for keeping
track of these exercise periods following termination for any reason of his or her
service relationship with the Company. The Company will not provide further notice of
such periods.
	 
	 	 
	Transferability:

	 	This Option may not be transferred.

 

 

     By your signature and the signature of the Company’s representative below, you and the Company
agree that this option is granted under and governed by the terms and conditions of the Stock
Option Agreement which is attached and made a part of this document.

     All capitalized terms in this Notice shall have the meaning ascribed to them in this Notice
or, if not otherwise defined herein, in the attached Stock Option Agreement.

     In addition, you agree and acknowledge that nothing in this Notice or the attached documents
confers upon you any right to continue your employment or consulting relationship with the Company
for any period of time, nor does it interfere in any way with your right or the Company’s right to
terminate that relationship at any time, for any reason, with or without cause.

	 	 	 	 	 	 	 
	 	 	 	 	OMEROS MEDICAL SYSTEMS, INC.
	 
	 	 	 	 	 	 
	/s/ Pamela Pierce Palmer

	 	 	 	By:
	 	/s/ Gregory A. Demopulos
	 

	 	 	 	 	 	 
	Pamela Pierce-Palmer, M.D., Ph.D.

	 	 	 	Name:
	 	Gregory A. Demopulos
	 

	 	 	 	Title:
	 	Chairman & CEO

 

 

OMEROS MEDICAL SYSTEMS, INC.

STOCK OPTION AGREEMENT

     1. Grant of Option. Omeros Medical Systems, Inc., a Washington corporation (the
“Company”), hereby grants to Pamela Pierce-Palmer, M.D., Ph.D. (“Optionee”), an
option (the “Option”) to purchase the total number of shares of Common Stock (the
“Shares”) set forth in the Notice of Stock Option Grant (the “Notice”), at the
exercise price per Share set forth in the Notice (the “Exercise Price”) subject to the
terms, definitions and provisions of this Agreement. All capitalized terms in this Agreement shall
have the meaning ascribed to them in the attached Appendix.

     2. Designation of Option. This Option is intended to be a Nonstatutory Stock Option.

     3. Exercise of Option. This Option shall be exercisable during its term in accordance
with the Vesting/Exercise Schedule set out in the Notice and with the provisions of Section 10 of
this Agreement as follows:

          (a) Right to Exercise.

               (i) This Option may not be exercised for a fraction of a share.

               (ii) In the event of Optionee’s death, disability or other termination of employment, the
exercisability of the Option is governed by Sections 5 and 6 below, subject to the limitations
contained in this Section 3.

               (iii) In no event may this Option be exercised after the Expiration Date of the Option as set
forth in the Notice.

          (b) Method of Exercise.

               (i) This Option shall be exercisable by execution and delivery of the Exercise Notice and
Restricted Stock Purchase Agreement attached hereto as Exhibit A, or any other form of
written notice approved for such purpose by the Company which shall state Optionee’s election to
exercise the Option, the number of Shares in respect of which the Option is being exercised, and
such other representations and agreements as to the holder’s investment intent with respect to such
Shares as may be required by the Company pursuant to the provisions of this Agreement. Such
written notice shall be signed by Optionee and shall be delivered to the Company by such means as
are determined by the Company in its discretion to constitute adequate delivery. The written
notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be
exercised upon receipt by the Company of such written notice accompanied by the Exercise Price.

               (ii) As a condition to the exercise of this Option and as further set forth in Section 10 of
this Agreement, Optionee agrees to make adequate provision for federal,

 

 

state or other tax withholding obligations, if any, which arise upon the vesting or exercise of the Option, or
disposition of Shares, whether by withholding, direct payment to the Company, or otherwise.

               (iii) The Company is not obligated, and will have no liability for failure, to issue or
deliver any Shares upon exercise of the Option unless such issuance or delivery would comply with
the Applicable Laws, with such compliance determined by the Company in consultation with its legal
counsel. This Option may not be exercised if the issuance of such Shares upon such exercise or the
method of payment of consideration for such shares would constitute a violation of any applicable
federal or state securities or other law or regulation, including any rule under Part 221 of
Title 12 of the Code of Federal Regulations as promulgated by the Federal Reserve Board. As a
condition to the exercise of this Option, the Company may require Optionee to make any
representation and warranty to the Company as may be required by the Applicable Laws. Assuming
such compliance, for income tax purposes the Shares shall be considered transferred to Optionee on
the date on which the Option is exercised with respect to such Shares.

     4. Method of Payment. Payment of the Exercise Price shall be by any of the following,
or a combination of the following, at the election of Optionee:

          (a) cash or check;

          (b) prior to the date, if any, upon which the Common Stock becomes a Listed Security, by
surrender of other shares of Common Stock of the Company that have an aggregate Fair Market Value
on the date of surrender equal to the Exercise Price of the Shares as to which the Option is being
exercised. In the case of shares acquired directly or indirectly from the Company, such shares
must have been owned by Optionee for more than six (6) months on the date of surrender (or such
other period of time as is necessary to avoid the Company’s incurring adverse accounting charges);
or

          (c) following the date, if any, upon which the Common Stock is a Listed Security, delivery of
a properly executed exercise notice together with irrevocable instructions to a broker approved by
the Company to deliver promptly to the Company the amount of sale required to pay the exercise
price.

     5. Termination of Relationship. Following the date of termination of Optionee’s
Continuous Service Status for any reason (the “Termination Date”), Optionee may exercise
the Option only as set forth in the Notice and this Section 5. To the extent that Optionee is not
entitled to exercise this Option as of the Termination Date, or if Optionee does not exercise this
Option within the Termination Period set forth in the Notice or the termination periods set forth
below, the Option shall terminate in its entirety. In no event may any Option be exercised after
the Expiration Date as set forth in the Notice.

          (a) Termination. In the event of termination of Optionee’s Continuous Service Status
other than as a result of Optionee’s disability or death, Optionee may, to the extent otherwise so
entitled at the date of such termination, exercise this Option during the Termination Period set
forth in the Notice.

-2-

 

          (b) Other Terminations. In connection with any termination other than a termination
covered by Section 5(a), Optionee may exercise the Option only as described below:

               (i) Termination upon Disability of Optionee. In the event of termination of
Optionee’s Continuous Service Status as a result of Optionee’s disability, Optionee may, but only
within twelve (12) months from the Termination Date, exercise this Option to the extent Optionee
was entitled to exercise it as of such Termination Date.

               (ii) Death of Optionee. In the event of the death of Optionee (a) during the term of
this Option and while an Employee or Consultant of the Company and having been in Continuous
Service Status since the date of grant of the Option, or (b) within thirty (30) days after
Optionee’s Termination Date, the Option may be exercised at any time within six (6) months
following the date of death by Optionee’s estate or by a person who acquired the right to exercise
the Option by bequest or inheritance, but only to the extent Optionee was entitled to exercise the
Option as of the Termination Date.

          (c) Buyout Provisions. The Company may at any time offer to buy out the Option for a
payment in cash or Shares based on such terms and conditions as the Company shall establish and
communicate to the Optionee at the time that such offer is made.

     6. Non-Transferability of Option. This Option may not be transferred in any manner
otherwise than by will or by the laws of descent or distribution and may be exercised during the
lifetime of Optionee only by him or her. The terms of this Option shall be binding upon the
executors, administrators, heirs, successors and assigns of Optionee.

     7. Tax Consequences. Below is a brief summary as of the date of this Option of
certain of the federal tax consequences of exercise of this Option and disposition of the Shares
under the laws in effect as of the Date of Grant. THIS SUMMARY IS INCOMPLETE, AND THE TAX LAWS AND
REGULATIONS ARE SUBJECT TO CHANGE. OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS
OPTION OR DISPOSING OF THE SHARES.

          Since this Option does not qualify as an incentive stock option under the Code, there may be a
regular federal (and state) income tax liability upon the exercise of the Option. Optionee will be
treated as having received compensation income (taxable at ordinary income tax rates) equal to the
excess, if any, of the fair market value of the Shares on the date of exercise over the Exercise
Price. If Optionee is an Employee, the Company will be required to withhold from Optionee’s
compensation or collect from Optionee and pay to the applicable taxing authorities an amount equal
to a percentage of this compensation income at the time of exercise. If Shares issued upon
exercise of a Nonstatutory Stock Option are held for at least one year, any gain realized on
disposition of the Shares will be treated as long-term capital gain for federal income tax
purposes.

     8. Lock-Up Agreement. In connection with the initial public offering of the Company’s
securities and upon request of the Company or the underwriters managing any underwritten offering
of the Company’s securities, Optionee hereby agrees not to sell, make any short sale of, loan,
grant any option for the purchase of, or otherwise dispose of any securities of

-3-

 

the Company however
and whenever acquired (other than those included in the registration) without the prior written
consent of the Company or such underwriters, as the case may be, for such period of time (not to
exceed 180 days) from the effective date of such registration as may be requested by the Company or
such managing underwriters and to execute an agreement reflecting the foregoing as may be requested
by the underwriters at the time of the public offering.

     9. Effect of Agreement. Optionee represents that he or she is familiar with the terms
and provisions of this Agreement (and has had an opportunity to consult counsel regarding the
Option terms), and hereby accepts this Option and agrees to be bound by its contractual terms as
set forth herein. Optionee hereby agrees to accept as binding, conclusive and final all decisions
and interpretations of the Company regarding any questions relating to the Option.

     10. Taxes.

          (a) As a condition of the exercise of this Option, the Optionee (or in the case of the
Optionee’s death, the person exercising the Option) shall make such arrangements as the Company may
require for the satisfaction of any applicable federal, state, local or foreign withholding tax
obligations that may arise in connection with the exercise of the Option and the issuance of
Shares. The Company shall not be required to issue any Shares under this Agreement until such
obligations are satisfied. If the Company allows the withholding or surrender of Shares to satisfy
an Optionee’s tax withholding obligations under this Section 10 (whether pursuant to Section 10(c),
(d) or (e), or otherwise), the Company shall not allow Shares to be withheld in an amount that
exceeds the minimum statutory withholding rates for federal and state tax purposes, including
payroll taxes.

          (b) In the case of an Employee and in the absence of any other arrangement, the Employee shall
be deemed to have directed the Company to withhold or collect from his or her compensation an
amount sufficient to satisfy such tax obligations from the next payroll payment otherwise payable
after the date of an exercise of the Option.

          (c) This Section 10(c) shall apply only after the date, if any, upon which the Common Stock
becomes a Listed Security. In the case of an Optionee other than an Employee (or in the case of an
Employee where the next payroll payment is not sufficient to satisfy such tax obligations, with
respect to any remaining tax obligations), in the absence of any other arrangement and to the
extent permitted under the Applicable Laws, the Optionee shall be deemed to have elected to have
the Company withhold from the Shares to be issued upon exercise of the Option that number of Shares
having a Fair Market Value determined as of the applicable Tax Date (as defined below) equal to the
amount required to be withheld. For purposes of this Section 10, the Fair Market Value of the
Shares to be withheld shall be determined on the date that the amount of tax to be withheld is to
be determined under the Applicable Laws (the “Tax Date”).

          (d) If permitted in writing by the Company, in its sole discretion, Optionee may satisfy his
or her tax withholding obligations upon exercise of an Option by surrendering to the Company Shares
that have a Fair Market Value determined as of the applicable Tax Date equal to the amount required
to be withheld. In the case of shares previously acquired from the

-4-

 

Company that are surrendered
under this Section 10(d), such Shares must have been owned by the Optionee for more than six (6)
months on the date of surrender (or such other period of time as is required for the Company to
avoid adverse accounting charges).

          (e) Any election or deemed election by an Optionee to have Shares withheld to satisfy tax
withholding obligations under Section 10(c) or (d) above shall be irrevocable as to the particular
Shares as to which the election is made and shall be subject to the consent or disapproval of the
Company. Any election by an Optionee under Section 10(d) above must be made on or prior to the
applicable Tax Date.

          (f) In the event an election to have Shares withheld is made by an Optionee and the Tax Date
is deferred under Section 83 of the Code because no election is filed under Section 83(b) of the
Code, the Optionee shall receive the full number of Shares with respect to which the Option is
exercised but such Optionee shall be unconditionally obligated to tender back to the Company the
proper number of Shares on the Tax Date.

     11. Adjustments Upon Changes in Capitalization, Merger or Certain Other Transactions.

          (a) Changes in Capitalization. Subject to any required action by the shareholders of
the Company, the number of Shares of Common Stock covered by the Option, as well as the price per
Share of Common Stock covered by the Option, shall be proportionately adjusted for any increase or
decrease in the number of issued Shares of Common Stock resulting from a stock split, reverse stock
split, stock dividend, combination, recapitalization or reclassification of the Common Stock, or
any other increase or decrease in the number of issued Shares of Common Stock effected without
receipt of consideration by the Company; provided, however, that conversion of any convertible
securities of the Company shall not be deemed to have been “effected without receipt of
consideration.” Such adjustment shall be made by the Company, and its determination in that
respect shall be final, binding and conclusive. Except as expressly provided herein, no issuance
by the Company of shares of stock of any class, or securities convertible into shares of stock of
any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the
number or price of Shares of Common Stock subject to an Option.

          (b) Dissolution or Liquidation. In the event of the dissolution or liquidation of the
Company, the Option will terminate immediately prior to the consummation of such action, unless
otherwise determined by the Company, in it sole discretion.

          (c) Corporate Transaction. In the event of a Corporate Transaction, each outstanding
Option shall be assumed or an equivalent option or right shall be substituted by such successor
corporation or a parent or subsidiary of such successor corporation (the “Successor
Corporation”), unless the Successor Corporation does not agree to assume the award or to
substitute an equivalent option or right, in which case such Option shall terminate upon the
consummation of the transaction.

          For purposes of this Section 11(c), an Option shall be considered assumed, without limitation,
if, at the time of issuance of the stock or other consideration upon a Corporate

-5-

 

Transaction each holder of an Option would be entitled to receive upon exercise of the award the same number and
kind of shares of stock or the same amount of property, cash or securities as such holder would
have been entitled to receive upon the occurrence of the transaction if the holder had been,
immediately prior to such transaction, the holder of the number of Shares of Common Stock covered
by the award at such time (after giving effect to any adjustments in the number of Shares covered
by the Option as provided for in this Section 11); provided that if such consideration received in
the transaction is not solely common stock of the Successor Corporation, the Company may, with the
consent of the Successor Corporation, provide for the consideration to be received upon exercise of
the award to be solely common stock of the Successor Corporation equal to the Fair Market Value of
the per Share consideration received by holders of Common Stock in the transaction.

          (d) Certain Distributions. In the event of any distribution to the Company’s
shareholders of securities of any other entity or other assets (other than dividends payable in
cash or stock of the Company) without receipt of consideration by the Company, the Company may, in
its sole discretion, appropriately adjust the price per Share of Common Stock covered by each
outstanding Option to reflect the effect of such distribution.

     12. Amendment of Option. In addition to any changes or adjustments that may be made
pursuant to Section 11 above, the Company’s Board of Directors shall have the authority to make the
following determinations with respect to, and amendments to, the Option without the consent of
Optionee: (a) waiver of any restriction applicable to the Option or the Optioned Stock; (b)
settlement in cash of the Option; (c) reduction in the exercise price of the Option to the Fair
Market Value of the Company’s Common Stock as of the date of such reduction in price; and (d) any
other amendment or adjustment that does not materially and adversely affect Optionee’s rights
hereunder.

     13. Miscellaneous.

          (a) Governing Law. This Agreement and all acts and transactions pursuant hereto and
the rights and obligations of the parties hereto shall be governed, construed and interpreted in
accordance with the laws of the State of Washington, without giving effect to principles of
conflicts of law.

          (b) Entire Agreement; Enforcement of Rights. This Agreement sets forth the entire
agreement and understanding of the parties relating to the subject matter herein and merges all
prior discussions between them. No modification of or amendment to this Agreement, nor any waiver
of any rights under this Agreement, shall be effective unless in writing signed by the parties to
this Agreement. The failure by either party to enforce any rights under this Agreement shall not
be construed as a waiver of any rights of such party.

          (c) Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good
faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement
for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance
of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance
of the Agreement shall be enforceable in accordance with its terms.

-6-

 

          (d) Construction. This Agreement is the result of negotiations between and has been
reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this
Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be
construed in favor of or against any one of the parties hereto.

          (e) Notices. Any notice required or permitted by this Agreement shall be in writing
and shall be deemed sufficient when delivered personally or sent by telegram or fax or forty-eight
(48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage
prepaid, and addressed to the party to be notified at such party’s address as set forth below or as
subsequently modified by written notice.

          (f) Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original and all of which together shall constitute one instrument.

          (g) Successors and Assigns. The rights and benefits of this Agreement shall inure to
the benefit of, and be enforceable by the Company’s successors and assigns. The rights and
obligations of Optionee under this Agreement may only be assigned with the prior written consent of
the Company.

          (h) Accredited Investor. The Optionee is an accredited investor as defined in Rule
501(a) of Regulation D promulgated under the Securities Act of 1933.

[Signature Page Follows]

-7-

 

     This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original and all of which together shall constitute one document.

	 	 	 	 	 	 	 	 	 
	Pamela Pierce-Palmer, M.D., Ph.D.	 	 	 	OMEROS MEDICAL SYSTEMS, INC.
	 
	 	 	 	 	 	 	 	 
	/s/ Pamela Pierce Palmer	 	 	 	By:	 	/s/ Gregory A. Demopulos
	 	 	 	 	 	 	 
	Dated:

	 	 	 	 	 	Name:
	 	Gregory A. Demopulos
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Title:
	 	Chairman & CEO

-8-

 

APPENDIX

          (a) “Affiliate” means an entity other than a Subsidiary (as defined below) which,
together with the Company, is under common control of a third person or entity.

          (b) “Applicable Laws” means the legal requirements relating to the administration of
stock option and grants under applicable U.S. state corporate laws, U.S. federal and applicable
state securities laws, the Code, any Stock Exchange rules or regulations and the applicable laws of
any other country or jurisdiction where the Option is granted under this Agreement, as such laws,
rules, regulations and requirements shall be in place from time to time.

          (c) “Board” means the Board of Directors of the Company.

          (d) “Code” means the Internal Revenue Code of 1986, as amended.

          (e) “Common Stock” means the Common Stock of the Company.

          (f) “Consultant” means any person, including an advisor, who is engaged by the Company
or any Parent, Subsidiary or Affiliate to render services and is compensated for such services, and
any director of the Company whether compensated for such services or not.

          (g) “Continuous Service Status” means the absence of any interruption or termination
of service as an Employee or Consultant. Continuous Service Status as an Employee or Consultant
shall not be considered interrupted in the case of: (i) sick leave; (ii) military leave; (iii) any
other leave of absence approved by the Administrator, provided that such leave is for a period of
not more than ninety (90) days, unless reemployment upon the expiration of such leave is guaranteed
by contract or statute, or unless provided otherwise pursuant to Company policy adopted from time
to time; or (iv) in the case of transfers between locations of the Company or between the Company,
its Parents, Subsidiaries, Affiliates or their respective successors. A change in status from an
Employee to a Consultant or from a Consultant to an Employee will not constitute an interruption of
Continuous Service Status.

          (h) “Corporate Transaction” means a sale of all or substantially all of the Company’s
assets, or a merger, consolidation or other capital reorganization of the Company with or into
another corporation.

          (i) “Director” means a member of the Board.

          (j) “Employee” means any person employed by the Company or any Parent, Subsidiary or
Affiliate, with the status of employment determined based upon such factors as are deemed
appropriate by the Administrator in its discretion, subject to any requirements of the Code or the
Applicable Laws. The payment by the Company of a director’s fee to a Director shall not be
sufficient to constitute “employment” of such Director by the Company.

          (k) “Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

 

          (l) “Fair Market Value” means, as of any date, the fair market value of the Common
Stock, as determined by the Administrator in good faith on such basis as it deems appropriate.
Whenever possible, the determination of Fair Market Value shall be based upon the closing price for
the Shares as reported in the Wall Street Journal for the applicable date.

          (m) “Listed Security” means any security of the Company that is listed or approved for
listing on a national securities exchange or designated or approved for designation as a national
market system security on an interdealer quotation system by the National Association of Securities
Dealers, Inc.

          (n) “Nonstatutory Stock Option” means an Option not intended to qualify as an
incentive stock option within the meaning of Section 422 of the Code.

          (o) “Option” means a stock option granted pursuant to this Agreement.

          (p) “Optioned Stock” means the Common Stock subject to an Option.

          (q) “Parent” means a “parent corporation,” whether now or hereafter existing, as
defined in Section 424(e) of the Code, or any successor provision.

          (r) “Share” means a share of the Common Stock, as adjusted in accordance with Section
11 of this Agreement.

          (s) “Stock Exchange” means any stock exchange or consolidated stock price reporting
system on which prices for the Common Stock are quoted at any given time.

          (t) “Subsidiary” means a “subsidiary corporation,” whether now or hereafter existing,
as defined in Section 424(f) of the Code, or any successor provision.

-2-

 

EXHIBIT A

OMEROS MEDICAL SYSTEMS, INC.

EXERCISE NOTICE AND RESTRICTED STOCK PURCHASE AGREEMENT

     This Agreement (“Agreement”) is made as of                     , by and between Omeros
Medical Systems, Inc., a Washington corporation (the “Company”), and Pamela Pierce-Palmer,
M.D., Ph.D. (“Purchaser”). To the extent any capitalized terms used in this Agreement are
not defined, they shall have the meaning ascribed to them in the Option Agreement (as defined
below).

     1. Exercise of Option. Subject to the terms and conditions hereof, Purchaser hereby
elects to exercise his or her option to purchase                      shares of the Common Stock (the
“Shares”) of the Company under and pursuant to the Stock Option Agreement dated December
11, 2001, (the “Option Agreement”). The purchase price for the Shares shall be $0.265 per
Share for a total purchase price of $                    . The term “Shares” refers to the purchased
Shares and all securities received in replacement of the Shares or as stock dividends or splits,
all securities received in replacement of the Shares in a recapitalization, merger, reorganization,
exchange or the like, and all new, substituted or additional securities or other properties to
which Purchaser is entitled by reason of Purchaser’s ownership of the Shares.

     2. Time and Place of Exercise. The purchase and sale of the Shares under this
Agreement shall occur at the principal office of the Company simultaneously with the execution and
delivery of this Agreement in accordance with the provisions of Section 3(b) of the Option
Agreement. On such date, the Company will deliver to Purchaser a certificate representing the
Shares to be purchased by Purchaser (which shall be issued in Purchaser’s name) against payment of
the exercise price therefor by Purchaser by (a) check made payable to the Company, (b) cancellation
of indebtedness of the Company to Purchaser, (c) delivery of shares of the Common Stock of the
Company in accordance with Section 4(b) of the Option Agreement, or (d) a combination of the
foregoing.

     3. Limitations on Transfer. In addition to any other limitation on transfer created
by applicable securities laws, Purchaser shall not assign, encumber or dispose of any interest in
the Shares except in compliance with the provisions below and applicable securities laws.

          (a) Right of First Refusal. Before any Shares held by Purchaser or any transferee of
Purchaser (either being sometimes referred to herein as the “Holder”) may be sold or
otherwise transferred (including transfer by gift or operation of law), the Company or its
assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions
set forth in this Section 3(a) (the “Right of First Refusal”).

               (i) Notice of Proposed Transfer. The Holder of the Shares shall deliver to the
Company a written notice (the “Notice”) stating: (i) the Holder’s bona fide intention to
sell or otherwise transfer such Shares; (ii) the name of each proposed purchaser or other
transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to each

 

 

Proposed Transferee; and (iv) the terms and conditions of each proposed sale or transfer. The
Holder shall offer the Shares at the same price (the “Offered Price”) and upon the same
terms (or terms as similar as reasonably possible) to the Company or its assignee(s).

               (ii) Exercise of Right of First Refusal. At any time within thirty (30) days after
receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the
Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to
any one or more of the Proposed Transferees, at the purchase price determined in accordance with
subsection (iii) below.

               (iii) Purchase Price. The purchase price (“Purchase Price”) for the Shares
purchased by the Company or its assignee(s) under this Section 3(a) shall be the Offered Price. If
the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash
consideration shall be determined by the Board of Directors of the Company in good faith.

               (iv) Payment. Payment of the Purchase Price shall be made, at the option of the
Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any
outstanding indebtedness, or by any combination thereof within 30 days after receipt of the Notice
or in the manner and at the times set forth in the Notice.

               (v) Holder’s Right to Transfer. If all of the Shares proposed in the Notice to be
transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s)
as provided in this Section 3(a), then the Holder may sell or otherwise transfer such Shares to
that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or
other transfer is consummated within 60 days after the date of the Notice and provided further that
any such sale or other transfer is effected in accordance with any applicable securities laws and
the Proposed Transferee agrees in writing that the provisions of this Section 3 shall continue to
apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the
Notice are not transferred to the Proposed Transferee within such period, or if the Holder proposes
to change the price or other terms to make them more favorable to the Proposed Transferee, a new
Notice shall be given to the Company, and the Company and/or its assignees shall again be offered
the Right of First Refusal before any Shares held by the Holder may be sold or otherwise
transferred.

               (vi) Exception for Certain Family Transfers. Anything to the contrary contained in
this Section 3(a) notwithstanding, the transfer of any or all of the Shares during Purchaser’s
lifetime or on Purchaser’s death by will or intestacy to Purchaser’s Immediate Family or a trust
for the benefit of Purchaser’s Immediate Family shall be exempt from the provisions of this Section
3(a). “Immediate Family” as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister. In such case, the transferee or other recipient
shall receive and hold the Shares so transferred subject to the provisions of this Section, and
there shall be no further transfer of such Shares except in accordance with the terms of this
Section 3.

-2-

 

          (b) Involuntary Transfer.

               (i) Company’s Right to Purchase upon Involuntary Transfer. In the event, at any time
after the date of this Agreement, of any transfer by operation of law or other involuntary transfer
(including death or divorce, but excluding a transfer to Immediate Family as set forth in Section
3(a)(vi) above) of all or a portion of the Shares by the record holder thereof, the Company shall
have an option to purchase all of the Shares transferred at the greater of the purchase price paid
by Purchaser pursuant to this Agreement or the fair market value of the Shares on the date of
transfer. Upon such a transfer, the person acquiring the Shares shall promptly notify the
Secretary of the Company of such transfer. The right to purchase such Shares shall be provided to
the Company for a period of thirty (30) days following receipt by the Company of written notice by
the person acquiring the Shares.

               (ii) Price for Involuntary Transfer. With respect to any stock to be transferred
pursuant to Section 3(b)(i), the price per Share shall be a price set by the Board of Directors of
the Company that will reflect the current value of the stock in terms of present earnings and
future prospects of the Company. The Company shall notify Purchaser or his or her executor of the
price so determined within thirty (30) days after receipt by it of written notice of the transfer
or proposed transfer of Shares. However, if the Purchaser does not agree with the valuation as
determined by the Board of Directors of the Company, the Purchaser shall be entitled to have the
valuation determined by an independent appraiser to be mutually agreed upon by the Company and the
Purchaser and whose fees shall be borne equally by the Company and the Purchaser.

          (c) Assignment. The right of the Company to purchase any part of the Shares may be
assigned in whole or in part to any shareholder or shareholders of the Company or other persons or
organizations.

          (d) Restrictions Binding on Transferees. All transferees of Shares or any interest
therein will receive and hold such Shares or interest subject to the provisions of this Agreement.
Any sale or transfer of the Company’s Shares shall be void unless the provisions of this Agreement
are satisfied.

          (e) Termination of Rights. The right of first refusal granted the Company by
Section 3(a) above and the option to repurchase the Shares in the event of an involuntary transfer
granted the Company by Section 3(b) above shall terminate upon the first sale of Common Stock of
the Company to the general public pursuant to a registration statement filed with and declared
effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended
(the “Securities Act”). Upon termination of the right of first refusal described in
Section 3(b) above, a new certificate or certificates representing the Shares not repurchased shall
be issued, on written request, without the legend referred to in Section 6(a)(ii) herein and
delivered to Purchaser.

     4. Investment and Taxation Representations. In connection with the purchase of the
Shares, Purchaser represents to the Company the following:

-3-

 

          (a) Purchaser is aware of the Company’s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and knowledgeable decision
to acquire the Shares. Purchaser is purchasing these securities for investment for his or her own
account only and not with a view to, or for resale in connection with, any “distribution” thereof
within the meaning of the Securities Act or under any applicable provision of state law. Purchaser
does not have any present intention to transfer the Shares to any person or entity.

          (b) Purchaser understands that the Shares have not been registered under the Securities Act by
reason of a specific exemption therefrom, which exemption depends upon, among other things, the
bona fide nature of Purchaser’s investment intent as expressed herein.

          (c) Purchaser further acknowledges and understands that the securities must be held
indefinitely unless they are subsequently registered under the Securities Act or an exemption from
such registration is available. Purchaser further acknowledges and understands that the Company is
under no obligation to register the securities. Purchaser understands that the certificate(s)
evidencing the securities will be imprinted with a legend which prohibits the transfer of the
securities unless they are registered or such registration is not required in the opinion of
counsel for the Company.

          (d) Purchaser is familiar with the provisions of Rules 144 and 701, each promulgated under the
Securities Act, which, in substance, permit limited public resale of “restricted securities”
acquired, directly or indirectly, from the issuer of the securities (or from an affiliate of such
issuer), in a non-public offering subject to the satisfaction of certain conditions. Purchaser
understands that the Company provides no assurances as to whether he or she will be able to resell
any or all of the Shares pursuant to Rule 144 or Rule 701, which rules require, among other things,
that the Company be subject to the reporting requirements of the Securities Exchange Act of 1934,
as amended, that resales of securities take place only after the holder of the Shares has held the
Shares for certain specified time periods, and under certain circumstances, that resales of
securities be limited in volume and take place only pursuant to brokered transactions.
Notwithstanding this paragraph (d), Purchaser acknowledges and agrees to the restrictions set forth
in paragraph (e) below.

          (e) Purchaser further understands that in the event all of the applicable requirements of
Rule 144 or 701 are not satisfied, registration under the Securities Act, compliance with
Regulation A, or some other registration exemption will be required; and that, notwithstanding the
fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement securities other than in
a registered offering and otherwise than pursuant to Rule 144 or 701 will have a substantial burden
of proof in establishing that an exemption from registration is available for such offers or sales,
and that such persons and their respective brokers who participate in such transactions do so at
their own risk.

          (f) Purchaser understands that Purchaser may suffer adverse tax consequences as a result of
Purchaser’s purchase or disposition of the Shares. Purchaser represents that Purchaser has
consulted any tax consultants Purchaser deems advisable in

-4-

 

connection with the purchase or
disposition of the Shares and that Purchaser is not relying on the Company for any tax advice.

          (g) Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act of 1933.

     5. Restrictive Legends and Stop-Transfer Orders.

          (a) Legends. The certificate or certificates representing the Shares shall bear the
following legends (as well as any legends required by applicable state and federal corporate and
securities laws):

	 	(i)	 	THE SHARES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A
VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION
THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT
AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN
OPINION OF COUNSEL FOR THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
	 
	 	(ii)	 	THE SHARES REPRESENTED BY THIS
CERTIFICATE MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE
TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

          (b) Stop-Transfer Notices. Purchaser agrees that, in order to ensure compliance with
the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions
to its transfer agent, if any, and that, if the Company transfers its own securities, it may make
appropriate notations to the same effect in its own records.

          (c) Refusal to Transfer. The Company shall not be required (i) to transfer on its
books any Shares that have been sold or otherwise transferred in violation of any of the provisions
of this Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay
dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.

     6. No Employment Rights. Nothing in this Agreement shall affect in any manner
whatsoever the right or power of the Company, or a parent or subsidiary of the Company, to
terminate Purchaser’s employment or consulting relationship, for any reason, with or without cause.

-5-

 

     7. Lock-Up Agreement. In connection with the initial public offering of the Company’s
securities and upon request of the Company or the underwriters managing any underwritten offering
of the Company’s securities, Purchaser agrees not to sell, make any short sale of, loan, grant any
option for the purchase of, or otherwise dispose of any securities of the Company however or
whenever acquired (other than those included in the registration) without the prior written consent
of the Company or such underwriters, as the case may be, for such period of time (not to exceed 180
days) from the effective date of such registration as may be requested by the Company or such
managing underwriters and to execute an agreement reflecting the foregoing as may be requested by
the underwriters at the time of the public offering.

     8. Miscellaneous.

          (a) Governing Law. This Agreement and all acts and transactions pursuant hereto and
the rights and obligations of the parties hereto shall be governed, construed and interpreted in
accordance with the laws of the State of Washington, without giving effect to principles of
conflicts of law.

          (b) Entire Agreement; Enforcement of Rights. This Agreement sets forth the entire
agreement and understanding of the parties relating to the subject matter herein and merges all
prior discussions between them. No modification of or amendment to this Agreement, nor any waiver
of any rights under this Agreement, shall be effective unless in writing signed by the parties to
this Agreement. The failure by either party to enforce any rights under this Agreement shall not
be construed as a waiver of any rights of such party.

          (c) Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good
faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement
for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance
of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance
of the Agreement shall be enforceable in accordance with its terms.

          (d) Construction. This Agreement is the result of negotiations between and has been
reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this
Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be
construed in favor of or against any one of the parties hereto.

          (e) Notices. Any notice required or permitted by this Agreement shall be in writing
and shall be deemed sufficient when delivered personally or sent by telegram or fax or forty-eight
(48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage
prepaid, and addressed to the party to be notified at such party’s address as set forth below or as
subsequently modified by written notice.

          (f) Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original and all of which together shall constitute one instrument.

-6-

 

          (g) Successors and Assigns. The rights and benefits of this Agreement shall inure to
the benefit of, and be enforceable by the Company’s successors and assigns. The rights and
obligations of Purchaser under this Agreement may only be assigned with the prior written consent
of the Company.

[Signature Page Follows]

-7-

 

     The parties have executed this Exercise Notice and Restricted Stock Purchase Agreement as of
the date first set forth above.

	 	 	 	 	 
	 	 	COMPANY:
	 
	 	 	 	 
	 	 	OMEROS MEDICAL SYSTEMS, INC.
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	PURCHASER:
	 
	 	 	 	 
	 	 	Pamela Pierce-Palmer, M.D., Ph.D.
	 
	 	 	 	 
	 	 	 
	 	 	(Signature)
	 
	 	 	 	 
	 

	 	Address:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 

I,                                         , spouse of Pamela Pierce-Palmer, M.D., Ph.D., have read and hereby
approve the foregoing Agreement. In consideration of the Company’s granting my spouse the right to
purchase the Shares as set forth in the Agreement, I hereby agree to be irrevocably bound by the
Agreement and further agree that any community property or other such interest shall hereby be
similarly bound by the Agreement. I hereby appoint my spouse as my attorney-in-fact with respect
to any amendment or exercise of any rights under the Agreement.

	 	 	 
	 

	 	 
	 

	 	Spouse of Pamela Pierce-Palmer, M.D., Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]